ARBACLOFEN PLACARBIL, A NOVEL REFLUX INHIBITOR, IS SAFE AND WELL TOLERATED AT EFFICACIOUS DOSES IN SUBJECTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE

(1) UNIVERSITY OF WISCONSIN, SCHOOL OF MEDICINE Medicine, Madison, USA

(2) XenoPort, Inc., Santa Clara, United States

(3) Northwestern UniversityMedical School, Chicago, UnitedStates



This item was part of the Oesophageal, Gastric and Duodenal Disorders III session at UEG Week Barcelona 2010

This item can be cited as: Gut 2010; 59 (Suppl III) A343